Evidence map›Paper›PMID 40804314›Full record

ReviewHuman vaccines & immunotherapeutics2025

Approaches to assess new pneumococcal vaccines for immunogenicity, development and licensure.

Feroze A Ganaie, Moon H Nahm

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Vaccine Adjuvants and Delivery Systems: A Comprehensive Review.International journal of molecular sciences · 2026
    Review
  2. Article
  3. Article
  4. Erratum: Pneumococcal Vaccination of Adults in Italy: What Strategies?Journal of preventive medicine and hygiene · 2025
    Article
  5. Pneumococcal Vaccination of Adults in Italy: What Strategies?Journal of preventive medicine and hygiene · 2025
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Feroze A GanaieDivision of Pulmonary/Allergy/Critical Care, Department of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0003-1250-4604
Moon H NahmDivision of Pulmonary/Allergy/Critical Care, Department of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0002-6922-1042

Funding

Serogroup 19 capsule maleability leading to vaccine failureR21AI178586 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI NAHM, MOON H. · 2023 to 2024
$408k
NIAID NIH HHS R21 AI178586
6 · The paper itself

Abstract

Pneumococcal conjugate vaccines (PCVs) have transformed the prevention of

Indexed as

Immunogenicity, VaccinePneumococcal InfectionsPneumococcal VaccinesStreptococcus pneumoniaeVaccine DevelopmentAntibodies, BacterialHumansImmunoglobulin GLicensureSerogroupVaccine EfficacyVaccines, ConjugateAntibodies, BacterialImmunoglobulin GPneumococcal VaccinesVaccines, Conjugateimmune responseopsonophagocytic assaypneumococcal conjugate vaccinesStreptococcus pneumoniaeWHO-ELISA

Identifiers

PMID40804314
PMCPMC12351704

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.